Down 28% from Oct 23 to Nov 6 while the S&P 500 fell 3%.
−2Volatility
URGN's Quality Score fell 1 point on Fri, Nov 6, to 1. Trading went back to normal after a busy day.
Follow URGN's trial news. Pro members can get an alert when UroGen Pharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 9.0% a day with no profit behind it |
| Latest filing | 8-K, Nov 4 |
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
After its last 4 reports it closed -0.6% on average, higher 2 of 4 times.
About 2 quarters
CFO Chris Degnan sold 2,202 shares on Oct 8. 9 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
URGN is #122 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 122 |
Expected to report Tue Mar 2, before the open (in 113 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $89.0M, 224% more than a year ago; a loss of $0.03 a share, from $0.69.
“The increase was driven by the continued commercial launch of ZUSDURI.”
URGN's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
| Measure | Figure |
|---|---|
| JELMYTO net product revenue | about $90M |
“The revised outlook reflects a one-time unfavorable gross-to-net adjustment of approximately $1.5 million related to a CMS discard drug provision true-up, as well as ongoing competitive clinical trial enrollment activity in the United States that has affected JELMYTO patient starts in low-grade upper tract urothelial cancer.”
From its results filing (SEC filing · Nov 4)
Sales grew 20% a year over 3 years, fiscal 2022 to 2025.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -4.0% | -16.4% | not yet |
| Aug 5, 2026 | +5.6% | +16.3% | +18.0% |
| May 6, 2026 | +5.8% | +10.2% | +25.1% |
Sales grew in six of the last seven years, to $110M in 2025. It lost money in each of the eight years.
RSI 18.1, MACD below signal, below both averages. Not scored.
3 insiders sold $3.2M across 5 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
“We do not know whether other competitors in the NMIBC space are already developing, or plan to develop, UTUC treatments.”
URGN scores 1 today, which Breakaway calls Below Average. It is #122 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 28% from Oct 23 to Nov 6 while the S&P 500 fell 3%. Cash lasts about 2 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
URGN scores 1 today, which Breakaway calls Below Average (0 to 5). That is #122 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind URGN's 1.
3 insiders sold $3.2M across 5 filings in the last 6 months. No open-market buys on record. The newest is Chris Degnan, Chief Financial Officer, who sold $81K on Oct 8. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.